Drug pleiotropy
in pharmacology, a drug's actions other than those for which it was developed
In pharmacology, pleiotropy includes all of a drug's actions other than those for which the agent was specifically developed. It may include adverse effects which are detrimental ones, but is often used to denote additional beneficial effects.
For example, statins are HMG-CoA reductase inhibitors that primarily act by decreasing cholesterol synthesis, but which are believed to have other beneficial effects, including acting as antioxidants and stabilizing atherosclerotic plaques. Steroid drugs, such as prednisone and prednisolone, have pleiotropic effects, including systemic ones, for the same reason that endogenous steroid hormones do: cells throughout the body have receptors that can respond to them, because the endogenous ones are endocrine messengers.
Another example is melatonin, which has a wide range of effects on biological systems on multiple scales, from modulating the circadian rhythm and inducing sleep via the activation of melatoninergic receptors, to recepto-independent antioxydative and anti-inflammatory effects over all organs down to cells.
“Drug pleiotropy” enters the record as in pharmacology, a drug's actions other than those for which it was developed. Crown Archives preserves that source wording while asking what Drug, pleiotropy and pharmacology can confirm, complicate or overturn.
Why this record matters
“Drug pleiotropy” is worth following because a concise public description often conceals a longer documentary argument. Here, Drug, pleiotropy and pharmacology provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Jul 29, 2026. The linked authority identifier is Q7204482. None of the 0 selected statements returned an explicit reference.
A concise general-reference account can conceal disagreements about scope, terminology or the weight assigned to individual sources. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Drug pleiotropy”, its source revision and the description used here.
- Expand the search: follow Drug pleiotropy primary sources, Drug pleiotropy archive and Drug research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Drug pleiotropy”?
- Which cited source is closest to the event, object or claim?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Drug pleiotropy” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.